Related Experiment Videos
[Clinical and laboratory screening studies on urea cycle defects].
Yan-ling Yang1, Fang Sun, Ning Qian
1Department of Pediatrics, Peking University First Hospital, Beijing 100034, China.
This study examined 254 patients with high ammonia levels and found that 26 (10.2%) had urea cycle defects (UCDs). UCDs were diagnosed using blood and urine tests, and in some cases, liver biopsies and genetic testing. The most common UCD was OTC deficiency. Symptoms began as early as 3 days old and included seizures, vomiting, and liver problems. Blood ammonia levels were very high in most patients. Four patients were diagnosed after death. Of the 21 treated patients, 14 improved, but seven died from complications. One patient who had a liver transplant from his mother showed normal health for two years. The study shows that UCDs are a major cause of high ammonia levels and that early diagnosis and treatment can improve outcomes.
Area of Science:
- Inborn errors of metabolism within pediatric medicine
- Clinical biochemical diagnostics in metabolic disorders
- Genetic screening in neonatal and pediatric care
Background:
Hyperammonemia remains a diagnostic challenge in clinical settings. Prior research has shown that elevated ammonia levels can stem from various causes, including liver disease and metabolic defects. However, the specific contribution of urea cycle defects (UCDs) to hyperammonemia has remained unclear. No prior work had resolved the frequency of UCDs among hyperammonemic patients. This gap motivated a closer look at UCDs as a potential cause of neurological and hepatic symptoms. The lack of comprehensive screening protocols for UCDs in hyperammonemic cases created uncertainty in diagnosis and treatment. This uncertainty drove the need for a study focused on UCD prevalence and clinical patterns. Existing knowledge suggested UCDs are rare, but this study aimed to quantify their role in a clinical cohort. The study aimed to clarify how often UCDs are misdiagnosed or overlooked in hyperammonemia.
Purpose Of The Study:
The study aimed to determine the frequency of UCDs among patients with hyperammonemia and to describe their clinical and laboratory features. Researchers focused on identifying UCDs as a cause of neurological and hepatic symptoms in this population. The specific problem addressed was the lack of data on UCDs in hyperammonemic patients. The motivation stemmed from the need to improve early diagnosis and treatment outcomes. The study sought to clarify how many hyperammonemic cases are attributable to UCDs. It also aimed to describe the age of onset and clinical manifestations. The researchers wanted to assess the impact of UCDs on prognosis and survival. The ultimate goal was to guide diagnostic and therapeutic approaches in hyperammonemia.
Main Methods:
The study analyzed 254 patients with hyperammonemia over seven years. Blood amino acids, urinary organic acids, and acylcarnitine profiles were tested to detect UCDs. Liver pathology and genetic testing confirmed three cases of citrullinemia type II. The diagnostic approach combined biochemical and genetic methods. Clinical data included age of onset, family history, and presenting symptoms. Neurological and hepatic outcomes were tracked over time. Follow-up data were collected for 21 patients who received treatment. The study compared UCD subtypes and their associated clinical features.
Main Results:
Of 254 hyperammonemic patients, 26 (10.2%) had UCDs. The most common subtype was OTC deficiency, affecting 15 patients. Five had citrullinemia type I, three had citrullinemia type II, and three had arginemia. The age of onset ranged from 3 days to 13 years. Eleven percent of cases developed hyperammonemic encephalopathy in the neonatal period. Fifty percent of patients showed symptoms between 1 and 12 months of age. Thirty-four percent presented with seizures, psychomotor delay, or unconsciousness. Six patients had liver dysfunction as the primary complaint. Blood ammonia levels ranged from 58 to 259 micromol/L at first presentation.
Conclusions:
UCDs are a frequent cause of congenital hyperammonemia in this cohort. The study found UCDs in 10.2% of hyperammonemic patients. The results suggest UCDs contribute significantly to neurological and hepatic symptoms. Early diagnosis and treatment improved outcomes in some cases. The study supports the need for UCD screening in hyperammonemic patients. Blood ammonia testing should be followed by etiological analysis. The findings highlight the importance of genetic and biochemical testing. These conclusions align with the authors' claim that UCDs are a major cause of hyperammonemia.
Frequently Asked Questions
Ornithine transcarbamylase (OTC) deficiency was the most common, affecting 15 of 26 patients with UCDs.
Diagnoses were made using blood amino acids, urinary organic acids, and acylcarnitine profile analyses. Liver pathology and genetic testing confirmed three cases of citrullinemia type II.
Twenty of 26 patients had liver dysfunction, likely due to the metabolic burden of ammonia accumulation and impaired urea cycle function.
Blood ammonia levels ranged from 58 to 259 micromol/L at first presentation, indicating the severity of hyperammonemia in UCD patients.
Fourteen patients showed clinical improvement, while seven died from complications like encephalopathy or bleeding.
The authors propose that blood ammonia testing and further etiological analysis should be part of the differential diagnosis for neurological and hepatic abnormalities.